Ivan Lolli
Impact in
- Genetics top 2%
- Glioma Diagnosis and Treatment
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
- Co-authors
- Roberta Rudà (10 shared papers)Francesco Pasqualetti (6 shared papers)Riccardo Soffietti (6 shared papers)Marica Eoli (7 shared papers)Vittorina Zagonel (8 shared papers)Giuseppe Lombardi (8 shared papers)Gian Luca De Salvo (8 shared papers)Simona Rizzato (6 shared papers)
- Journals
- Journal of Clinical Oncology (9 papers)Annals of Oncology (4 papers)Journal of Neuro-Oncology (3 papers)European Journal of Cancer (2 papers)Clinical Cancer Research (1 paper)
- Partner nations
- ItalyUnited States
In The Last Decade
Ivan Lolli
37 papers receiving 664 citations
Ivan Lolli's Hit Papers
Peers
Comparison fields: 5 of 60
- Genetics 388
- Cancer Research 202
- Oncology 190
- Pulmonary and Respiratory Medicine 197
- Neurology 91
Countries citing papers authored by Ivan Lolli
This map shows the geographic impact of Ivan Lolli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Lolli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Lolli more than expected).
Fields of papers citing papers by Ivan Lolli
This network shows the impact of papers produced by Ivan Lolli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Lolli. The network helps show where Ivan Lolli may publish in the future.
Co-authors
The 25 scholars most cited alongside Ivan Lolli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial Hit paper breakdown → | 2018 | 257 |
| 2 | 2013 | 54 | |
| 3 | 2008 | 47 | |
| 4 | 2021 | 36 | |
| 5 | 2007 | 35 | |
| 6 | 2020 | 28 | |
| 7 | 2014 | 27 | |
| 8 | 2020 | 21 | |
| 9 | 2020 | 16 | |
| 10 | 2021 | 16 | |
| 11 | 2013 | 14 | |
| 12 | 2020 | 12 | |
| 13 | 2019 | 12 | |
| 14 | 2011 | 11 | |
| 15 | 2006 | 10 | |
| 16 | 2012 | 10 | |
| 17 | 2022 | 10 | |
| 18 | 2005 | 9 | |
| 19 | 2023 | 8 | |
| 20 | 2018 | 5 |
About Ivan Lolli
Ivan Lolli is a scholar working on Oncology, Genetics, Pulmonary and Respiratory Medicine, Cancer Research and Pathology and Forensic Medicine, having authored 40 papers that have together received 672 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (16 papers), Colorectal Cancer Treatments and Studies (8 papers), Brain Metastases and Treatment (8 papers), Cancer Treatment and Pharmacology (6 papers), Cancer, Hypoxia, and Metabolism (6 papers), Lung Cancer Treatments and Mutations (5 papers), Genetic factors in colorectal cancer (4 papers) and Cancer Genomics and Diagnostics (4 papers). The work is most often cited by research in Genetics (388 citations), Cancer Research (202 citations), Oncology (190 citations), Pulmonary and Respiratory Medicine (197 citations) and Neurology (91 citations). Ivan Lolli has collaborated with scholars based in Italy and United States. Frequent co-authors include Roberta Rudà, Francesco Pasqualetti, Riccardo Soffietti, Marica Eoli, Vittorina Zagonel, Giuseppe Lombardi, Gian Luca De Salvo, Simona Rizzato, Alba A. Brandes and Stefano Indraccolo. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Neuro-Oncology, European Journal of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.